Mobenakin

Mobenakin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Mobenakin

Mobenakin is a pharmaceutical compound used primarily in the treatment of certain cardiovascular conditions. It is classified as a beta-blocker, which functions by blocking the effects of epinephrine (adrenaline) on the heart and blood vessels, thereby reducing heart rate, blood pressure, and strain on the heart.

Pharmacology[edit]

Mobenakin works by selectively inhibiting beta-1 adrenergic receptors in the heart. This action decreases the heart rate and contractility, leading to a reduction in cardiac output and blood pressure. Unlike non-selective beta-blockers, Mobenakin has a higher affinity for beta-1 receptors, which are predominantly found in cardiac tissue, thus minimizing the risk of bronchoconstriction in patients with respiratory conditions.

Indications[edit]

Mobenakin is indicated for the management of:

Hypertension (high blood pressure)
Angina pectoris (chest pain)
Heart failure
Arrhythmias (irregular heartbeats)

Contraindications[edit]

Mobenakin should not be used in patients with:

Severe bradycardia (slow heart rate)
Heart block greater than first degree
Cardiogenic shock
Decompensated heart failure

Side Effects[edit]

Common side effects of Mobenakin include:

Fatigue
Dizziness
Cold extremities
Bradycardia

Less common but serious side effects may include:

Heart block
Worsening of heart failure
Bronchospasm

Dosage and Administration[edit]

Mobenakin is typically administered orally, with the dosage adjusted based on the patient's response and clinical condition. It is important to start with a low dose and titrate gradually to minimize the risk of adverse effects.

Mechanism of Action[edit]

Mobenakin's primary mechanism involves the competitive antagonism of catecholamines at beta-1 adrenergic receptors. This leads to decreased cyclic AMP levels, reduced calcium influx, and ultimately, decreased myocardial contractility and heart rate.

Research and Development[edit]

Mobenakin was developed in the late 20th century as part of a new generation of cardioselective beta-blockers. Ongoing research is focused on its potential benefits in reducing cardiovascular events in high-risk populations.